Xenpozyme(olipudase alfa)
Xenpozyme (olipudase alfa) is an enzyme pharmaceutical. Olipudase alfa was first approved as Xenpozyme on 2022-06-24. It is used to treat lysosomal storage diseases in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Xenpozyme
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xenpozyme | Biologic Licensing Application | 2025-03-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| lysosomal storage diseases | — | D016464 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
olipudase alfa, Xenpozyme, Genzyme Corporation | |||
| 2029-08-31 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type a niemann-pick disease | D052536 | EFO_1001380 | E75.240 | 3 | 4 | 1 | — | 3 | 9 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Niemann-pick diseases | D009542 | — | E75.24 | 3 | 3 | — | — | 3 | 8 |
| Type c niemann-pick disease | D052556 | Orphanet_646 | E75.242 | 3 | 3 | — | — | 2 | 7 |
| Lipidoses | D008064 | — | E75.6 | 1 | 2 | — | — | 1 | 3 |
| Pick disease of the brain | D020774 | EFO_0003096 | G31.01 | 1 | 1 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Frontotemporal dementia | D057180 | — | G31.0 | 1 | — | — | — | — | 1 |
| Primary progressive aphasia | D018888 | EFO_0009053 | G31.01 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Olipudase alfa |
| INN | olipudase alfa |
| Description | Olipudase alfa, sold under the brand name Xenpozyme, is a medication used for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) type A/B or type B.
|
| Classification | Enzyme |
| Drug class | enzymes |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3707358 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12835 |
| UNII ID | 6D5766Q4OP (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Xenpozyme – Sanofi
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 256 documents
View more details
Safety
Black-box Warning
Black-box warning for: Xenpozyme
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
109 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use